<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149199</url>
  </required_header>
  <id_info>
    <org_study_id>D589SC00001</org_study_id>
    <secondary_id>2013-004474-96</secondary_id>
    <nct_id>NCT02149199</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.</brief_title>
  <acronym>SYGMA1</acronym>
  <official_title>A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is
      effective in treating asthma when used 'as needed' in patients with milder asthma. The
      efficacy of Symbicort® 'as needed' will be compared with: 1) terbutaline Turbuhaler® 'as
      needed' and with 2) Pulmicort (budesonide) Turbuhaler® twice daily plus terbutaline
      Turbuhaler® 'as needed'.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 52-week, double-blind, randomised, multi-centre, parallel-group, Phase III study in
      patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort®
      (budesonide/formoterol) Turbuhaler® 160/4.5 μg 'as needed' compared with terbutaline
      Turbuhaler® 0.4 mg 'as needed' and with Pulmicort® (budesonide) Turbuhaler® 200 μg twice
      daily plus terbutaline Turbuhaler® 0.4 mg 'as needed'
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2014</start_date>
  <completion_date type="Actual">August 2, 2017</completion_date>
  <primary_completion_date type="Actual">August 2, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)</measure>
    <time_frame>Weekly, up to 52 weeks</time_frame>
    <description>A well-controlled asthma week is defined as the fulfilment of both conditions A) and B) below: A) Two or more of the following criteria are fulfilled: − No more than 2 days with a daily asthma symptom score &gt;1 − No more than 2 days of 'as needed' medication use, up to a maximum of 4 occasions per week (multiple occasions per day should be regarded as separate occasions) − Morning PEF ≥80% of Predicted Normal every day B) Both of the following criteria are fulfilled: − No nighttime awakenings due to asthma − No additional inhaled and/or systemic glucocorticosteroid treatment due to asthma. The binary variable well-controlled asthma week was derived for each patient and study week. In addition, for each week, the percent of patients with well-controlled asthma week was derived. It is required that the eDiary had to be completed on at least 5 days in a week to be a well-controlled asthma week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing at Least One Severe Asthma Exacerbation</measure>
    <time_frame>Day 1 up to 52 weeks</time_frame>
    <description>A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation</measure>
    <time_frame>Day 1 up to 52 weeks</time_frame>
    <description>A moderate exacerbation is defined as a deterioration of asthma requiring a change in treatment, i.e. initiation of prescribed additional ICS treatment to avoid progression of the worsening of asthma to a severe exacerbation.
A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Study weeks 0,4,16,28,40,52</time_frame>
    <description>Overall estimate of FEV1 (mL) pre-bronchodilator change from baseline. Baseline is the measurement at Visit 3 (prior to first dose of Investigational Product) from MMRM (mixed model repeated measures analysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Morning Peak Expiratory Flow (PEF)</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Morning peak expiratory flow (eDiary) change from baseline over the randomised treatment period. Baseline is defined as the mean of all non-missing morning measurements during the last 10 days of the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Evening PEF</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Evening peak expiratory flow (eDiary) change from baseline during the randomised treatment period. Baseline is defined as the mean of all non-missing evening measurements during the last 10 days of the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Number of Inhalations of 'as Needed' Medication.</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>'As needed' inhalations change from baseline over the randomised treatment period. Baseline is defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Asthma Symptom Score</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Asthma symptom score (eDiary) change from baseline during the randomised treatment period. Symptom score is entered morning and evening by the patient on a 4-point scale from 0 to 3 with higher values indicating more severe symptoms. Asthma symptom score is then the sum of the day and night scores, which implies a range of scores from 0 - 6, with higher values indicating more severe symptoms. Baseline is defined as the mean of all non-missing measurements during the last 10 days of the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Night-time awakenings (%) due to asthma change from baseline. Variable analysed is the proportion (%) of nights during the relevant period with night-time awakenings. Baseline refers to the last 10 nights of the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Symptom-free Days</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Symptom-free days (%) change from baseline during the randomised treatment period.Variable analysed is the proportion (%) of symptom-free days during the relevant period. Baseline refers to the last 10 days of the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of 'As Needed' Free Days</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>'As needed' free days (%) change from baseline during the randomised treatment period. An 'as needed' free day is defined as a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of 'as needed' free days during the relevant period. Baseline refers to the last 10 days of the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of Asthma Control Days</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Asthma control days (%) change from baseline. An asthma control day is defined as the fulfilment of all of the following criteria; a day and night with no asthma symptoms, a night with no awakenings due to asthma symptoms and a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of asthma control days during the randomised treatment period. Baseline refers to the last 10 days of the run-in period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Study Specific Asthma Related Discontinuation</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Study specific asthma related discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poorly Controlled Asthma Weeks</measure>
    <time_frame>Weekly for up to 52 weeks</time_frame>
    <description>A poorly-controlled asthma week is defined as a week meeting any one of the following conditions: Two or more consecutive days with awakenings due to asthma on both nights; A recorded use of 'as needed' medication for symptom relief of at least 3 occasions per day, for at least 2 consecutive days; Additional systemic GCS treatment required for severe exacerbation. If there were sufficient data within a week available to confirm the week was not poorly-controlled, the week is labelled as 'does not meet criteria for poorly-controlled'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma</measure>
    <time_frame>Day 1 up to 52 weeks</time_frame>
    <description>Additional steroids for asthma includes any additional inhaled and/or systemic glucocorticosteroids treatment due to asthma while in the randomised treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)</measure>
    <time_frame>Study weeks 0,4,16,28,40,52</time_frame>
    <description>Asthma Control Questionnaire 5-item version score change from baseline. ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))</measure>
    <time_frame>Study weeks 0,16,28,40,52</time_frame>
    <description>Asthma Quality of Life Questionnaire Standardised Version (AQLQ (S) overall score change from baseline. AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Controller Use Days</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>ICS controller use days (%) during the randomised treatment period is calculated as the cumulative number of days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma exacerbations and/or long term poor asthma control (all treatment groups), divided by the number of days in the randomised treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Severe Asthma Exacerbation Rate</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Severe asthma exacerbations over the randomised treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Moderate or Severe Asthma Exacerbation Rate</measure>
    <time_frame>up to 52 weeks</time_frame>
    <description>Moderate or severe asthma exacerbations during the randomised treatment period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3850</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Symbicort &quot;as needed&quot;+placebo Pulmicort bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' + Placebo Pulmicort Turbuhaler 200 μg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>terbutaline &quot;as needed&quot;+placebo Pulmicort bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>terbutaline Turbuhaler 0.4 mg 'as needed' + placebo Pulmicort 200 μg Turbuhaler bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmicort bid + terbutaline &quot;as needed&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmicort 200 μg Turbuhaler bid + terbutaline 0.4 mg Turbuhaler 'as needed'</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol 'as needed' + budesonide placebo bid</intervention_name>
    <description>Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment</description>
    <arm_group_label>Symbicort &quot;as needed&quot;+placebo Pulmicort bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbutaline 'as needed' + placebo budesonide bid</intervention_name>
    <description>Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment</description>
    <arm_group_label>terbutaline &quot;as needed&quot;+placebo Pulmicort bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide bid + terbutaline 'as needed'</intervention_name>
    <description>Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment</description>
    <arm_group_label>Pulmicort bid + terbutaline &quot;as needed&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA 1. Provision of informed consent prior to any study specific procedures.
        For patients under-age, signed informed consent from both the patient and the patient's
        parent/legal guardian is required 2. Male or Female, ≥12 years of age 3. Documented
        diagnosis of asthma for at least 6 months prior to Visit 1 4. Patients who are in need of
        Step 2 treatment according to Global Initiative for Asthma guidelines 5. Patients treated
        with 'as needed' inhaled short-acting bronchodilator(s) only should have pre-bronchodilator
        Forced Expiratory Volume in one second (FEV1) ≥ 60 % of Predicted Normal (PN) and
        post-bronchodilator FEV1 ≥ 80 % PN 6. Patients treated with low stable dose of inhaled
        corticosteroid or leukotriene antagonist in addition to 'as needed' use of inhaled
        short-acting bronchodilator(s) should have pre-bronchodilator FEV1 ≥80 % PN 7. Patients
        should have reversible airway obstruction 8. To be randomized patients must have used
        Bricanyl Turbuhaler 'as needed' on at least 3 separate days during the last week of the run
        in period. EXCLUSION CRITERIA 1. Patient has a history of life-threatening asthma including
        intubation and intensive care unit admission 2. Patient has had an asthma worsening
        requiring change in treatment other than inhaled short-acting bronchodilator(s) within 30
        days prior to Visit 1 or between Visits 1 and 2; or a treatment other than Bricanyl
        Turbuhaler from Visit 2 until randomization 3. Patient has required treatment with oral,
        rectal or parenteral glucocorticosteroids (GCS) within 30 days and/or depot parenteral GCS
        within 12 weeks prior to Visit 1 4. Smoker (current or previous) with a smoking history of
        ≥ 10 pack years 5. Pregnancy, breast-feeding or planned pregnancy during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul M O'Byrne, MB, FRCP(C), FRSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University, Hamilton, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bedford Park</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maroubra</city>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murdoch</city>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wollongong</city>
        <zip>2522</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alphaville</city>
        <zip>06454-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Botucatu</city>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <zip>41940-455</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <zip>09080-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04020-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04101-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sorocaba</city>
        <zip>18040-425</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dupnitsa</city>
        <zip>2600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gotse Delchev</city>
        <zip>2900</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Razgrad</city>
        <zip>7200</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roman</city>
        <zip>3130</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sandanski</city>
        <zip>2800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1152</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Velingrad</city>
        <zip>4600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vratsa</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5A 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sherwood Park</city>
        <state>Alberta</state>
        <zip>T8L 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maple Ridge</city>
        <state>British Columbia</state>
        <zip>V2X 2L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Vancouver</city>
        <state>British Columbia</state>
        <zip>V7M 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1N 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 3R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7N 3V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cornwall</city>
        <state>Ontario</state>
        <zip>K6H 4M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanata</city>
        <state>Ontario</state>
        <zip>K2L 3C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 0G6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3M 3E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2H 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9C 4Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 2G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 0M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1M 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Charles Borromee</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1G 3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G2J 0C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quillota</city>
        <zip>2260000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>404366</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7750495</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7980378</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>8380453</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talcahuano</city>
        <zip>4270918</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100043</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>430033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haikou</city>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hohhot</city>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wenzhou</city>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>CN-430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xi'an</city>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xi'an</city>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xiamen</city>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xuzhou</city>
        <zip>221006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berettyóújfalu</city>
        <zip>4100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1195</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edelény</city>
        <zip>3780</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hajdúnánás</city>
        <zip>4080</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monor</city>
        <zip>2200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mátészalka</city>
        <zip>4700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyírbátor</city>
        <zip>4300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4420</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7626</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7635</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucheon-si</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>362-804</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03312</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>07985</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>D.f.</city>
        <zip>03020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durango</city>
        <zip>43080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64461</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <zip>58070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>México</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>México</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villahermosa</city>
        <zip>86035</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cusco</city>
        <zip>CUSCO 01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>L18</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>L27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 31</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piura</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Surco</city>
        <zip>LIMA 33</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pasig City</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elbląg</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <zip>25-734</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-901</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-455</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-823</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-051</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-612</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skierniewice</city>
        <zip>96-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strzelce Opolskie</city>
        <zip>47-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>71-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Słupca</city>
        <zip>62-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turek</city>
        <zip>62-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-203</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>91-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bragadiru</city>
        <zip>077025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500051</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <zip>500283</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Constanta</city>
        <zip>900002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pitesti</city>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300310</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620219</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117630</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123995</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>142160</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <zip>440067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614056</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>6144090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint - Petersburg</city>
        <zip>196211</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint - Petersburg</city>
        <zip>196657</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St.Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <zip>362007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boksburg North</city>
        <zip>1460</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <zip>4037</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <zip>4170</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>1818</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middelburg</city>
        <zip>1055</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Queenswood</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stanger</city>
        <zip>4450</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Verulam</city>
        <zip>4345</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cherkasy</city>
        <zip>18009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49074</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76012</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61035</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61075</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61093</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <zip>43000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <zip>43024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <zip>79066</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69068</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bath</city>
        <zip>BA3 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leamington Spa</city>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mortimer Reading</city>
        <zip>RG7 3SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trowbridge</city>
        <zip>BA14 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dong Nai</city>
        <zip>810000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hai Phong</city>
        <zip>180000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <zip>100000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hochiminh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>Vietnam</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=2648&amp;filename=D589SC00001-statistical-analysis-plan-edition-4_29Sep2017_pdfa.pdf</url>
    <description>D589SC00001-statistical-analysis-plan-edition-4_29Sep2017_pdfa</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <results_first_submitted>August 2, 2018</results_first_submitted>
  <results_first_submitted_qc>August 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2019</results_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Terbutaline</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02149199/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT02149199/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5721 patients enrolled; 5003 run-in, 718 not run-in; 3849 randomised, 1154 not randomised: 1022 did not meet incl/excl criteria, 4 adverse event, 5 severe non-compliance to protocol, 104 subject decision, 7 subject lost to follow-up, 12 other reason.</recruitment_details>
      <pre_assignment_details>Eligibility was assessed at Visits 1, 2, 3. IC obtained at V1. At V2, eligible patients stopped prescribed asthma medication and entered a 2-4 week run-in period, treated only with SABA Bricanyl Turbuhaler 0.5 mg, ‘as needed’. Lung function was performed by spirometry to confirm eligibility. Eligible patients were randomised at Visit 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Bid + Symbicort ‘as Needed’</title>
          <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Bid + Terbutaline 'as Needed'</title>
          <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
        </group>
        <group group_id="P3">
          <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
          <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1277"/>
                <participants group_id="P2" count="1277"/>
                <participants group_id="P3" count="1282"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1144"/>
                <participants group_id="P2" count="1084"/>
                <participants group_id="P3" count="1135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="147"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study specific withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set includes all patients randomised and receiving any IP.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Bid + Symbicort ‘as Needed’</title>
          <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Bid + Terbutaline 'as Needed'</title>
          <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
        </group>
        <group group_id="B3">
          <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
          <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1277"/>
            <count group_id="B2" value="1277"/>
            <count group_id="B3" value="1282"/>
            <count group_id="B4" value="3836"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Age is being measured in years</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&gt;=12 - &lt;18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="173"/>
                    <measurement group_id="B4" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=18 - &lt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="711"/>
                    <measurement group_id="B2" value="739"/>
                    <measurement group_id="B3" value="736"/>
                    <measurement group_id="B4" value="2186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=50 - &lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="315"/>
                    <measurement group_id="B3" value="285"/>
                    <measurement group_id="B4" value="908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 - &lt;85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="777"/>
                    <measurement group_id="B2" value="771"/>
                    <measurement group_id="B3" value="797"/>
                    <measurement group_id="B4" value="2345"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="500"/>
                    <measurement group_id="B2" value="506"/>
                    <measurement group_id="B3" value="485"/>
                    <measurement group_id="B4" value="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian Or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340"/>
                    <measurement group_id="B2" value="336"/>
                    <measurement group_id="B3" value="347"/>
                    <measurement group_id="B4" value="1023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian Or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black Or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="721"/>
                    <measurement group_id="B2" value="726"/>
                    <measurement group_id="B3" value="728"/>
                    <measurement group_id="B4" value="2175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)</title>
        <description>A well-controlled asthma week is defined as the fulfilment of both conditions A) and B) below: A) Two or more of the following criteria are fulfilled: − No more than 2 days with a daily asthma symptom score &gt;1 − No more than 2 days of 'as needed' medication use, up to a maximum of 4 occasions per week (multiple occasions per day should be regarded as separate occasions) − Morning PEF ≥80% of Predicted Normal every day B) Both of the following criteria are fulfilled: − No nighttime awakenings due to asthma − No additional inhaled and/or systemic glucocorticosteroid treatment due to asthma. The binary variable well-controlled asthma week was derived for each patient and study week. In addition, for each week, the percent of patients with well-controlled asthma week was derived. It is required that the eDiary had to be completed on at least 5 days in a week to be a well-controlled asthma week.</description>
        <time_frame>Weekly, up to 52 weeks</time_frame>
        <population>Full analysis set. Patients with no evaluable weeks are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)</title>
          <description>A well-controlled asthma week is defined as the fulfilment of both conditions A) and B) below: A) Two or more of the following criteria are fulfilled: − No more than 2 days with a daily asthma symptom score &gt;1 − No more than 2 days of 'as needed' medication use, up to a maximum of 4 occasions per week (multiple occasions per day should be regarded as separate occasions) − Morning PEF ≥80% of Predicted Normal every day B) Both of the following criteria are fulfilled: − No nighttime awakenings due to asthma − No additional inhaled and/or systemic glucocorticosteroid treatment due to asthma. The binary variable well-controlled asthma week was derived for each patient and study week. In addition, for each week, the percent of patients with well-controlled asthma week was derived. It is required that the eDiary had to be completed on at least 5 days in a week to be a well-controlled asthma week.</description>
          <population>Full analysis set. Patients with no evaluable weeks are not included in the analysis.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4" spread="36.02"/>
                    <measurement group_id="O2" value="31.1" spread="34.90"/>
                    <measurement group_id="O3" value="44.4" spread="39.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Repeated measures logistic regression, with treatment, pre-study treatment, region and study week as fixed effects.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
            <estimate_desc>An odds ratio greater than 1 favours Symbicort 'as needed'</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority analysis based on CI instead of p-value, hence no p-value calculated for this analysis. Lower limit of the 2-sided 95% CI &gt;=0.8 indicates Symbicort 'as needed' is non-inferior to Pulmicort bid.</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing at Least One Severe Asthma Exacerbation</title>
        <description>A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids</description>
        <time_frame>Day 1 up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing at Least One Severe Asthma Exacerbation</title>
          <description>A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="152"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox-regression model with randomised treatment, pre-study treatment, severe exacerbations in the last 12 months (0, &gt;=1) and region as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.435</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.328</ci_lower_limit>
            <ci_upper_limit>0.577</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 indicates that Symbicort 'as needed' prolongs the time to first severe exacerbation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.524</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with randomised treatment, pre-study treatment, severe exacerbations in the last 12 months (0,&gt;=1) and region as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.901</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.653</ci_lower_limit>
            <ci_upper_limit>1.242</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 indicates that Symbicort 'as needed' prolongs the time to first severe exacerbation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation</title>
        <description>A moderate exacerbation is defined as a deterioration of asthma requiring a change in treatment, i.e. initiation of prescribed additional ICS treatment to avoid progression of the worsening of asthma to a severe exacerbation.
A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids</description>
        <time_frame>Day 1 up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation</title>
          <description>A moderate exacerbation is defined as a deterioration of asthma requiring a change in treatment, i.e. initiation of prescribed additional ICS treatment to avoid progression of the worsening of asthma to a severe exacerbation.
A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                    <measurement group_id="O2" value="274"/>
                    <measurement group_id="O3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with randomised treatment, pre-study treatment, severe exacerbations in the last 12 months (0,&gt;=1) and region as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.429</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.348</ci_lower_limit>
            <ci_upper_limit>0.528</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 indicates that Symbicort 'as needed' prolongs the time to first moderate or severe exacerbation.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.436</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with randomised treatment, pre-study treatment, severe exacerbations in the last 12 months (0,&gt;=1) and region as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.910</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.718</ci_lower_limit>
            <ci_upper_limit>1.153</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 indicates that Symbicort 'as needed' prolongs the time to first moderate or severe exacerbation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Overall estimate of FEV1 (mL) pre-bronchodilator change from baseline. Baseline is the measurement at Visit 3 (prior to first dose of Investigational Product) from MMRM (mixed model repeated measures analysis).</description>
        <time_frame>Study weeks 0,4,16,28,40,52</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Overall estimate of FEV1 (mL) pre-bronchodilator change from baseline. Baseline is the measurement at Visit 3 (prior to first dose of Investigational Product) from MMRM (mixed model repeated measures analysis).</description>
          <population>Full analysis set.</population>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="47.6" upper_limit="82.4"/>
                    <measurement group_id="O2" value="11.2" lower_limit="-6.4" upper_limit="28.9"/>
                    <measurement group_id="O3" value="119.3" lower_limit="101.9" upper_limit="136.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with treatment, pre-study treatment, region, visit and (treatment x visit) as fixed, patient as random and baseline FEV1 as continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>53.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>29.1</ci_lower_limit>
            <ci_upper_limit>78.5</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'. This is the estimate across all treatment visits.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with treatment, pre-study treatment, region, visit and (treatment x visit) as fixed, patient as random and baseline FEV1 as continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-54.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-78.8</ci_lower_limit>
            <ci_upper_limit>-29.8</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'. This is the estimate across all treatment visits.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in Morning Peak Expiratory Flow (PEF)</title>
        <description>Morning peak expiratory flow (eDiary) change from baseline over the randomised treatment period. Baseline is defined as the mean of all non-missing morning measurements during the last 10 days of the run-in period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in Morning Peak Expiratory Flow (PEF)</title>
          <description>Morning peak expiratory flow (eDiary) change from baseline over the randomised treatment period. Baseline is defined as the mean of all non-missing morning measurements during the last 10 days of the run-in period.</description>
          <population>Full analysis set.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.97" lower_limit="-6.86" upper_limit="-1.09"/>
                    <measurement group_id="O2" value="-15.92" lower_limit="-18.80" upper_limit="-13.04"/>
                    <measurement group_id="O3" value="6.01" lower_limit="3.13" upper_limit="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with randomised treatment, pre-study treatment and region as factors and baseline PEF as a continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>11.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.89</ci_lower_limit>
            <ci_upper_limit>16.00</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with randomised treatment, pre-study treatment and region as factors and baseline PEF as a continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.03</ci_lower_limit>
            <ci_upper_limit>-5.93</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in Evening PEF</title>
        <description>Evening peak expiratory flow (eDiary) change from baseline during the randomised treatment period. Baseline is defined as the mean of all non-missing evening measurements during the last 10 days of the run-in period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in Evening PEF</title>
          <description>Evening peak expiratory flow (eDiary) change from baseline during the randomised treatment period. Baseline is defined as the mean of all non-missing evening measurements during the last 10 days of the run-in period.</description>
          <population>Full analysis set</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.20" lower_limit="-14.01" upper_limit="-8.39"/>
                    <measurement group_id="O2" value="-22.15" lower_limit="-24.96" upper_limit="-19.34"/>
                    <measurement group_id="O3" value="-4.97" lower_limit="-7.77" upper_limit="-2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with randomised treatment, pre-study treatment and region as factors and baseline PEF as a continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>10.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.99</ci_lower_limit>
            <ci_upper_limit>14.90</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with randomised treatment, pre-study treatment and region as factors and baseline PEF as a continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-6.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.18</ci_lower_limit>
            <ci_upper_limit>-2.29</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in Number of Inhalations of 'as Needed' Medication.</title>
        <description>'As needed' inhalations change from baseline over the randomised treatment period. Baseline is defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in Number of Inhalations of 'as Needed' Medication.</title>
          <description>'As needed' inhalations change from baseline over the randomised treatment period. Baseline is defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day.</description>
          <population>Full analysis set.</population>
          <units>Number of inhalations per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.82"/>
                    <measurement group_id="O2" value="-0.82" spread="0.92"/>
                    <measurement group_id="O3" value="-1.06" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in Asthma Symptom Score</title>
        <description>Asthma symptom score (eDiary) change from baseline during the randomised treatment period. Symptom score is entered morning and evening by the patient on a 4-point scale from 0 to 3 with higher values indicating more severe symptoms. Asthma symptom score is then the sum of the day and night scores, which implies a range of scores from 0 - 6, with higher values indicating more severe symptoms. Baseline is defined as the mean of all non-missing measurements during the last 10 days of the run-in period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in Asthma Symptom Score</title>
          <description>Asthma symptom score (eDiary) change from baseline during the randomised treatment period. Symptom score is entered morning and evening by the patient on a 4-point scale from 0 to 3 with higher values indicating more severe symptoms. Asthma symptom score is then the sum of the day and night scores, which implies a range of scores from 0 - 6, with higher values indicating more severe symptoms. Baseline is defined as the mean of all non-missing measurements during the last 10 days of the run-in period.</description>
          <population>Full analysis set</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" lower_limit="-0.27" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-0.11" lower_limit="-0.15" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.32" lower_limit="-0.36" upper_limit="-0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with randomised treatment, pre-study treatment and region as factors and baseline asthma symptom score as a continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.18</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>Mean difference less than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with randomised treatment, pre-study treatment and region as factors and baseline asthma symptom score as a continuous covariate.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
            <estimate_desc>Mean difference less than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma</title>
        <description>Night-time awakenings (%) due to asthma change from baseline. Variable analysed is the proportion (%) of nights during the relevant period with night-time awakenings. Baseline refers to the last 10 nights of the run-in period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma</title>
          <description>Night-time awakenings (%) due to asthma change from baseline. Variable analysed is the proportion (%) of nights during the relevant period with night-time awakenings. Baseline refers to the last 10 nights of the run-in period.</description>
          <population>Full analysis set.</population>
          <units>% of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="24.0"/>
                    <measurement group_id="O2" value="-4.6" spread="23.4"/>
                    <measurement group_id="O3" value="-9.8" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Symptom-free Days</title>
        <description>Symptom-free days (%) change from baseline during the randomised treatment period.Variable analysed is the proportion (%) of symptom-free days during the relevant period. Baseline refers to the last 10 days of the run-in period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Symptom-free Days</title>
          <description>Symptom-free days (%) change from baseline during the randomised treatment period.Variable analysed is the proportion (%) of symptom-free days during the relevant period. Baseline refers to the last 10 days of the run-in period.</description>
          <population>Full analysis set</population>
          <units>% of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="25.9"/>
                    <measurement group_id="O2" value="1.3" spread="24.8"/>
                    <measurement group_id="O3" value="6.8" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of 'As Needed' Free Days</title>
        <description>'As needed' free days (%) change from baseline during the randomised treatment period. An 'as needed' free day is defined as a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of 'as needed' free days during the relevant period. Baseline refers to the last 10 days of the run-in period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of 'As Needed' Free Days</title>
          <description>'As needed' free days (%) change from baseline during the randomised treatment period. An 'as needed' free day is defined as a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of 'as needed' free days during the relevant period. Baseline refers to the last 10 days of the run-in period.</description>
          <population>Full analysis set</population>
          <units>% of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="31.0"/>
                    <measurement group_id="O2" value="45.0" spread="30.7"/>
                    <measurement group_id="O3" value="51.7" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Percentage of Asthma Control Days</title>
        <description>Asthma control days (%) change from baseline. An asthma control day is defined as the fulfilment of all of the following criteria; a day and night with no asthma symptoms, a night with no awakenings due to asthma symptoms and a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of asthma control days during the randomised treatment period. Baseline refers to the last 10 days of the run-in period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Percentage of Asthma Control Days</title>
          <description>Asthma control days (%) change from baseline. An asthma control day is defined as the fulfilment of all of the following criteria; a day and night with no asthma symptoms, a night with no awakenings due to asthma symptoms and a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of asthma control days during the randomised treatment period. Baseline refers to the last 10 days of the run-in period.</description>
          <population>Full analysis set</population>
          <units>% of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="23.9"/>
                    <measurement group_id="O2" value="12.8" spread="23.3"/>
                    <measurement group_id="O3" value="18.5" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Study Specific Asthma Related Discontinuation</title>
        <description>Study specific asthma related discontinuation</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Study Specific Asthma Related Discontinuation</title>
          <description>Study specific asthma related discontinuation</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Poorly Controlled Asthma Weeks</title>
        <description>A poorly-controlled asthma week is defined as a week meeting any one of the following conditions: Two or more consecutive days with awakenings due to asthma on both nights; A recorded use of 'as needed' medication for symptom relief of at least 3 occasions per day, for at least 2 consecutive days; Additional systemic GCS treatment required for severe exacerbation. If there were sufficient data within a week available to confirm the week was not poorly-controlled, the week is labelled as 'does not meet criteria for poorly-controlled'.</description>
        <time_frame>Weekly for up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Poorly Controlled Asthma Weeks</title>
          <description>A poorly-controlled asthma week is defined as a week meeting any one of the following conditions: Two or more consecutive days with awakenings due to asthma on both nights; A recorded use of 'as needed' medication for symptom relief of at least 3 occasions per day, for at least 2 consecutive days; Additional systemic GCS treatment required for severe exacerbation. If there were sufficient data within a week available to confirm the week was not poorly-controlled, the week is labelled as 'does not meet criteria for poorly-controlled'.</description>
          <population>Full analysis set</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="13.3"/>
                    <measurement group_id="O2" value="9.7" spread="13.8"/>
                    <measurement group_id="O3" value="6.7" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma</title>
        <description>Additional steroids for asthma includes any additional inhaled and/or systemic glucocorticosteroids treatment due to asthma while in the randomised treatment period.</description>
        <time_frame>Day 1 up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma</title>
          <description>Additional steroids for asthma includes any additional inhaled and/or systemic glucocorticosteroids treatment due to asthma while in the randomised treatment period.</description>
          <population>Full analysis set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="345"/>
                    <measurement group_id="O3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with randomised treatment, pre-study treatment and region as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.413</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.343</ci_lower_limit>
            <ci_upper_limit>0.497</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 indicates that Symbicort 'as needed' prolongs the time to first additional steroids.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.175</p_value>
            <method>Regression, Cox</method>
            <method_desc>Cox regression model with randomised treatment, pre-study treatment and region as covariates.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.865</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.701</ci_lower_limit>
            <ci_upper_limit>1.067</ci_upper_limit>
            <estimate_desc>A hazard ratio less than 1 indicates that Symbicort 'as needed' prolongs the time to first additional steroids.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)</title>
        <description>Asthma Control Questionnaire 5-item version score change from baseline. ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided.</description>
        <time_frame>Study weeks 0,4,16,28,40,52</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)</title>
          <description>Asthma Control Questionnaire 5-item version score change from baseline. ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided.</description>
          <population>Full analysis set.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" lower_limit="-0.36" upper_limit="-0.29"/>
                    <measurement group_id="O2" value="-0.17" lower_limit="-0.21" upper_limit="-0.14"/>
                    <measurement group_id="O3" value="-0.48" lower_limit="-0.51" upper_limit="-0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with treatment, pre-study treatment, region, visit and (treatment x visit) as fixed, patient as random and baseline ACQ-5 as continuous covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.154</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.203</ci_lower_limit>
            <ci_upper_limit>-0.105</ci_upper_limit>
            <estimate_desc>Mean difference less than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with treatment, pre-study treatment, region, visit and (treatment x visit) as fixed, patient as random and baseline ACQ-5 as continuous covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.149</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.198</ci_upper_limit>
            <estimate_desc>Mean difference less than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))</title>
        <description>Asthma Quality of Life Questionnaire Standardised Version (AQLQ (S) overall score change from baseline. AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items.</description>
        <time_frame>Study weeks 0,16,28,40,52</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))</title>
          <description>Asthma Quality of Life Questionnaire Standardised Version (AQLQ (S) overall score change from baseline. AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items.</description>
          <population>Full analysis set.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.313" lower_limit="0.276" upper_limit="0.351"/>
                    <measurement group_id="O2" value="0.186" lower_limit="0.148" upper_limit="0.225"/>
                    <measurement group_id="O3" value="0.415" lower_limit="0.377" upper_limit="0.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with treatment, pre-study treatment, region, visit and treatment x visit as fixed, patient as random and baseline AQLQ(S) as continuous covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM with treatment, pre-study treatment, region, visit and treatment x visit as fixed, patient as random and baseline AQLQ(S) as continuous covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.102</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.155</ci_lower_limit>
            <ci_upper_limit>-0.049</ci_upper_limit>
            <estimate_desc>Mean difference greater than 0 favours Symbicort 'as needed'.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Controller Use Days</title>
        <description>ICS controller use days (%) during the randomised treatment period is calculated as the cumulative number of days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma exacerbations and/or long term poor asthma control (all treatment groups), divided by the number of days in the randomised treatment period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Controller Use Days</title>
          <description>ICS controller use days (%) during the randomised treatment period is calculated as the cumulative number of days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma exacerbations and/or long term poor asthma control (all treatment groups), divided by the number of days in the randomised treatment period.</description>
          <population>Full analysis set.</population>
          <units>% of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8" spread="28.7"/>
                    <measurement group_id="O2" value="5.6" spread="16.8"/>
                    <measurement group_id="O3" value="85.6" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Severe Asthma Exacerbation Rate</title>
        <description>Severe asthma exacerbations over the randomised treatment period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Severe Asthma Exacerbation Rate</title>
          <description>Severe asthma exacerbations over the randomised treatment period.</description>
          <population>Full analysis set</population>
          <units>exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.06" upper_limit="0.09"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.16" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.09" lower_limit="0.07" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model with treatment, pre-study treatment, severe exacerbations in the last 12 months (0,&gt;=1) and region as covariates</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.27</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>A rate ratio less than 1 indicates a lower rate of severe exacerbations in the Symbicort 'as needed' treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.279</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model with treatment, pre-study treatment, severe exacerbations in the last 12 months (0,&gt;=1) and region as covariates</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
            <estimate_desc>A rate ratio less than 1 indicates a lower rate of severe exacerbations in the Symbicort 'as needed' treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Moderate or Severe Asthma Exacerbation Rate</title>
        <description>Moderate or severe asthma exacerbations during the randomised treatment period.</description>
        <time_frame>up to 52 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Bid + Symbicort ‘as Needed’</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Bid + Terbutaline 'as Needed'</title>
            <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
          <group group_id="O3">
            <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
            <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Moderate or Severe Asthma Exacerbation Rate</title>
          <description>Moderate or severe asthma exacerbations during the randomised treatment period.</description>
          <population>Full analysis set</population>
          <units>exacerbations per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1277"/>
                <count group_id="O2" value="1277"/>
                <count group_id="O3" value="1282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.12" upper_limit="0.17"/>
                    <measurement group_id="O2" value="0.36" lower_limit="0.31" upper_limit="0.42"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.13" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model with treatment, pre-study treatment, severe exacerbations in the last 12 months (0,&gt;=1) and region as covariates</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>A rate ratio less than 1 indicates a lower rate of moderate or severe exacerbations in the Symbicort 'as needed' treatment group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.663</p_value>
            <method>Negative binomial model</method>
            <method_desc>Negative binomial model with treatment, pre-study treatment, severe exacerbations in the last 12 months (0,&gt;=1) and region as covariates</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
            <estimate_desc>A rate ratio less than 1 indicates a lower rate of moderate or severe exacerbations in the Symbicort 'as needed' treatment group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were summarised from Visit 2 up to the follow-up visit at week 54. Serious adverse events were recorded from the time of informed consent up to the follow-up visit at week 54.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Bid + Symbicort ‘as Needed’</title>
          <description>Placebo for budesonide (Placebo Turbuhaler) + Symbicort Turbuhaler (budesonide/formoterol 160/4.5 μg)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Bid + Terbutaline 'as Needed'</title>
          <description>Placebo for budesonide (Placebo Turbuhaler) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
        </group>
        <group group_id="E3">
          <title>Pulmicort Bid + Terbutaline 'as Needed'</title>
          <description>Pulmicort Turbuhaler (budesonide 200 μg) + Terbutaline Turbuhaler 0.4 mg 'as needed'</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1277"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1277"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abcess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Keratitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1277"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="1277"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Intervertebral disc injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Lumbar limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chrondropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Uterine leimyoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Patient-device incompatibility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Nephrolothiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1277"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="1277"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1277"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1277"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA version 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="1277"/>
                <counts group_id="E2" subjects_affected="378" subjects_at_risk="1277"/>
                <counts group_id="E3" subjects_affected="360" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="86" subjects_affected="71" subjects_at_risk="1277"/>
                <counts group_id="E2" events="95" subjects_affected="76" subjects_at_risk="1277"/>
                <counts group_id="E3" events="125" subjects_affected="93" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="90" subjects_affected="75" subjects_at_risk="1277"/>
                <counts group_id="E2" events="95" subjects_affected="79" subjects_at_risk="1277"/>
                <counts group_id="E3" events="98" subjects_affected="84" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="1277"/>
                <counts group_id="E2" events="41" subjects_affected="34" subjects_at_risk="1277"/>
                <counts group_id="E3" events="54" subjects_affected="48" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="39" subjects_affected="33" subjects_at_risk="1277"/>
                <counts group_id="E2" events="44" subjects_affected="41" subjects_at_risk="1277"/>
                <counts group_id="E3" events="48" subjects_affected="37" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="44" subjects_affected="23" subjects_at_risk="1277"/>
                <counts group_id="E2" events="54" subjects_affected="25" subjects_at_risk="1277"/>
                <counts group_id="E3" events="32" subjects_affected="29" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="40" subjects_affected="32" subjects_at_risk="1277"/>
                <counts group_id="E2" events="125" subjects_affected="95" subjects_at_risk="1277"/>
                <counts group_id="E3" events="61" subjects_affected="50" subjects_at_risk="1282"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="1277"/>
                <counts group_id="E2" events="32" subjects_affected="28" subjects_at_risk="1277"/>
                <counts group_id="E3" events="19" subjects_affected="19" subjects_at_risk="1282"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stefan Ivanov</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>000000000000</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

